Hepatitis B virus X (HBx) protein implicated in the development of liver cancer may inhibit the function of p53 tumor suppressor protein through cytoplasmic retention of p53 protein. Here, we attempt to investigate whether the functional inhibition of p53 protein by HBx protein is reversible. First, we provide the evidence for the association of endogenous p53 protein with HBx by co-immunoprecipitation in stable Chang cells that express HBx protein in an inducible manner (ChangX-34). By immuno¯uorescence microscopy, the major location of p53 protein of ChangX-34 cells was con®rmed at the nuclear periphery as well as in the cytoplasm where HBx protein is mainly expressed. Surprisingly, anticancer drug, adriamycin induces the nuclear translocation of p53 protein sequestered in the cytoplasm. This change is accompanied by the restoration of p53 activity, which results in increased transcriptional activity at the p53-responsive DNA elements as well as increase of p21 WAF1 mRNA expression. Further, we observed the induction of cell death and G1 arrest in these cells upon adriamycin treatment regardless of HBx expression. Together, we demonstrate that functional inhibition of p53 protein through its cytoplasmic retention by HBx protein is reversible. These results may be extended into other tumors of which p53 activity is modulated by viral oncoproteins.
Introduction
Chronic infection by hepatitis B virus (HBV) is associated with high incidence of hepatocellular carcinoma (HCC). Among HBV gene products, hepatitis B virus (HBx) protein is likely to play a causative role in the development of HCC. Introduction of HBx gene into rodent cells causes cellular transformation (HoÈ hne et al., 1990) and the transforming activity is con®rmed by the HBx transgenic mice, which developed HCC (Kim et al., 1991) .
HBx is a multifunctional transactivator for various viral and cellular genes (Natoli et al., 1995) . Transactivation function of HBx involves both activation of signal transduction cascades and direct protein-protein interactions. HBx can transactivate several signaling transduction pathways including protein kinase C (KekuleÈ et al., 1993) , ras/raf/MAP kinase (Benn and Schneider, 1994; Benn et al., 1996) , Jak1 kinase (Lee and Yun, 1998) and src kinase (Klein et al., 1999) . In addition, HBx directly interacts with transcription machinery such as RNA polymerase (Cheong et al., 1995) , TATA-binding protein and TF IIB (Haviv et al., 1998) and other cellular proteins such as p53 tumor suppressor protein. Thus, the pleiotropic activity of HBx may contribute to the modulation of gene expression, which ®nally leads to the formation of liver cancer.
p53 protein is a common target site in molecular pathogenesis of DNA tumor virus. Many viral oncoproteins disrupt p53 activity through direct protein-protein interaction (Teodoro and Branton, 1997) . These include large T antigen of simian virus 40 (Peden et al., 1989) , E6 protein of human papillomavirus (Schener et al., 1990; Thomas et al., 1996) , E1B 55-kDa of adenovirus (Rubenwolf et al., 1997) and HBx protein of HBV Lin et al., 1997) . Direct association between HBx and p53 proteins is observed with HBx-GST fusion proteins in vitro or with in vitro translated proteins (Truant et al., 1995) . This association is suggested to be responsible for the mutual interference in the transactivation by HBx and p53 (Lin et al., 1997) , and for blocking p53 entry into the nucleus in the HBx transgenic mouse (Ueda et al., 1995) . Moreover, these interactions may relieve the p53-mediated inhibition of viral replication (Lee et al., 1995) . Thus, it is a general idea that modulation of p53 activity in viral pathogenesis is a prerequisite for persistent replication of viral DNA as well as deranged cell cycle control in host cells. Despite the important role of p53 in viral pathogenesis, however, no one has demonstrated in vivo association of HBx with p53 in liver cells. In addition, cytoplasmic localization of p53 protein is never observed in either human hepatoma cells or liver specimens with preneoplastic nodules and HCC (Henkler et al., 1995; Greenblatt et al., 1997) . Therefore, in human liver, it remains unclear for the actual association of these proteins and subsequent eects in HBx-induced hepatocarcinogenesis.
p53 activity in cancer cells is an important factor in determining ecient cell death evoked by chemother-apeutic drug or radiation. Radiation or drug treatment on cells results in an accumulation of p53 protein probably through posttranscriptional modi®cation of p53 protein itself (Chresta et al., 1996) . Accumulated p53 induces a number of downstream target genes such as Fas, Killer/DR5 or bax, thereby mediating apoptosis (McCurrach et al., 1997; MuÈ ller et al., 1997; Houghton, 1999; Wu et al., 1999) . Many cancer cells, however, contain mutant p53 gene or nonfunctional p53 protein modulated by viral oncoproteins. Therefore, cellular responses to drug or radiation in those cancer cells are expected to be altered and inecient. In fact, drug treatment induces rapid apoptosis in cells with wild-type p53, but not in p53 null teratocarcinoma cells (Zamble et al., 1998) . And it is assumed that cells with p53-binding viral oncoproteins behave as if they have mutant p53 gene. However, it has never been addressed in detail how wild-type p53 protein bound to viral oncoproteins responds to radiation or drug treatment.
In the present study, we take advantage of using human liver cells stably expressing HBx protein and demonstrate the cytoplasmic sequestration of endogenous p53 protein in HBx-dependent manner. We also provide the evidence that p53-mediated cellular responses to chemotherapeutic drug can be restored in these cells.
Results

Expression of HBx and p53 proteins in HBx-expressing Chang liver cells
We have established HBx protein-expressing Chang liver cell line (ChangX-34 cells) in a doxycyclineinducible manner in which HBx was tagged with HA at the carboxyl-terminus. Basal expression of HBx protein was observed even in the absence of doxycycline treatment. When the cells were stimulated with 2 mg/ ml of doxycycline, HBx mRNA increased by more than 50-fold in a time-dependent manner (Kang H-J et al., submitted). The maximal increase of HBx protein was observed at 24 h after treatment and remained high up to 72 h ( Figure 1a ). Densitometry analysis demonstrated that HBx protein increased up to 7 ± 10-fold after normalization to the constitutive a-tubulin content. We next examined expression of p53 protein in these cells. Since Chang liver cells were known to contain wild-type p53 protein (Kim et al., 1998a) , we used a combination of several anti-p53 antibodies to increase the sensitivity of detection. When the cells were extracted with RIPA buer, both HBx and p53 proteins were detected in the supernatant (Figure 1b) . The expression level of p53 protein in these cells was not changed after treatment with doxycycline.
HBx protein associates with p53 protein in ChangX-34 cells
To investigate the interaction between HBx and p53 proteins, the total cell lysates of ChangX-34 cells were immunoprecipitated with anti-p53 antibody and Western blot analysis was then carried out using anti-HA antibody (Figure 2 ). Little binding of HBx protein with p53 protein was observed in the cell lysates prepared without doxycycline treatment, whereas a signi®cant amount of HBx protein was co-immunoprecipitated with anti-p53 antibody upon doxycycline treatment (Figure 2a ). The level of HBx protein in the 1/20 of the lysates used for immunoprecipitation indicated that most of HBx protein induced by doxycycline was bound to p53 molecules. The speci®city of the interaction was con®rmed by immunoprecipitating the Figure 1 Western blot analysis of HBx and p53 protein expressions in ChangX-34 cells. (a) After ChangX-34 cells were treated with 2 mg/ml of doxycycline (Dox) for 0 ± 72 h, the cell lysates were prepared using RIPA buer and subjected to SDS ± PAGE. The immunoblot was performed using anti-HA antibody. The protein concentration in each cell lysate was normalized by the level of a-tubulin content. (b) ChangX-34 cells were treated with doxycycline for 24 h and extracted with RIPA buer. The supernatant (s) and the pellet (p) were subjected to SDS ± PAGE and subsequently immunoblotted using anti-HA antibody, antip53 antibody and anti-a tubulin antibody (Figure 3a) . In contrast, an intense staining of HBx protein was mainly observed at the nuclear periphery and in the cytoplasm of ChangX-34 cells treated with 2 mg/ml of doxycycline for 24 h. It should be noted that HBx protein in ChangX-34 cells was not equally distributed in the cytoplasm, but localized at the nuclear periphery with an intense staining (yellow spots) and partly in the nucleus.
As expected, p53 protein in Chang liver cells was weak and observed only in the nucleus (Figure 3b, upper panel, open arrows) . In the absence of doxycycline treatment, p53 protein in ChangX-34 cells could be found both in the nucleus (open arrows) and in the nuclear periphery/cytoplasm (closed arrows). However, it should be mentioned that boundary of the nucleus expressing p53 protein was sometimes not clear and larger than DAPI staining (data not shown). Therefore, it is likely that the p53 protein may be localized both in the nucleus and at the nuclear periphery in some cells. When four dierent sets of immuno¯uorescence staining results were reviewed, 77% of cells expressed p53 protein in the nucleus including nuclear periphery and the rest of them (23%) mainly expressed p53 at the nuclear periphery/ cytoplasm. When ChangX-34 cells were treated with doxycycline, p53 protein was almost exclusively localized at the nuclear periphery and in the cytoplasm and a few were found in the nucleus. Thus, retention of p53 protein by HBx mainly occurred at the nuclear periphery. Therefore, the data suggest that induced HBx protein by doxycycline eciently bound to p53 protein as evidenced by co-immunoprecipitation and resulted in the retention of the latter protein at the nuclear periphery and in the cytoplasm.
Relocalization of p53 protein at the nucleus upon treatment with adriamycin
Cytoplasmic sequestration of p53 protein is one of the mechanisms by which the function of p53 protein is impaired during viral pathogenesis. We then asked whether the function of p53 protein in ChangX-34 cells was lost irreversibly. It is known that genotoxic stress induces posttranscriptional modi®cation and stabilization of p53, thereby resulting in accumulation of cellular p53 level (Chresta et al., 1996; MuÈ ller et al., 1997) . Therefore, we investigated whether adriamycin, one of the chemotherapeutic agents, would change the subcellular localization of p53, when p53 remained bound to HBx. When Chang liver cells were treated with adriamycin (1 mg/ml) for 20 h, an intense staining of p53 protein was clearly observed in the nucleus ( Figure 3b , lower panel). Remarkably, in ChangX-34 cells the same intense staining of p53 protein was found in the nucleus upon adriamycin treatment regardless of the presence of doxycycline. Increase of p53 protein level upon adriamycin treatment was shown in Western blot analysis (Figure 4b ).
Adriamycin increases p53-mediated transcriptional activity in ChangX-34
Reappearance of p53 protein in the nucleus in ChangX-34 cells upon adriamycin treatment led us to investigate whether p53-mediated transcriptional activity can be restored upon adriamycin treatment even in the presence of HBx protein. In Chang cells, adriamycin induced a strong activation from the reporter gene fused to p53 responsive DNA elements that have previously been shown to be sucient for p53-mediated transactivation (Jiang et al., 1993) . In contrast, upon adriamycin treatment transcriptional activity was not induced from G5BCAT, the GAL4-dependent CAT reporter gene (Jiang et al., 1993) , indicating that transcriptional activation is mediated by p53 protein in the cells (Figure 4a ). Speci®city of p53- Figure 4 The p53-dependent transcriptional activity in ChangX-34 cells upon adriamycin treatment. (a) Chang or ChangX-34 cells were transfected with G5BCAT control vector (solid bar) or p53CAT vector (gray bar) and treated with adriamycin in the presence or absence of 2 mg/ml doxycycline for 36 h. Cell extracts were prepared by freeze/thaw and CAT activity was determined on the basis of an equal amount of protein lysates as described in Materials and methods. (b) Chang or ChangX-34 cells were treated with doxycycline and/or adriamycin for 36 h, if necessary. Changes in endogenous p53 protein and p21 WAF1 mRNA expression were examined by Western blot analysis and Northern blot analysis, respectively mediated activation was also con®rmed by co-transfection of p53 expression vector (Figure 4a, right panel) . First of all, we have noticed that the basal p53CAT activity was always reduced by 35 ± 60% in the presence of doxycycline ( Figure 4a , right panel; compare lane 4 to 6) in three independent experiments. In addition, partial inhibition of p21 (Figure 3b ). Therefore, these results strongly support that a chemotherapeutic drug can restore the function of sequestered p53 protein.
Adriamycin induces severe cell death in ChangX-34 cells
Since adriamycin restores the function of sequestered p53 protein, we tested whether recovery of p53 function can be accompanied by cellular responses. When Chang cells were treated with adriamycin for 36 h, cells were either arrested at G1 phase or underwent cell death with a dramatic increase in sub-G1 population ( Figure 5 and Table 1 ). Figure 5 confers red color for cells in G1 phase (large peak) or G2/M phase (small peak), the hatched area for cells in S phase and blue color for cell debris. The cell debris is proportionally increased with the propidium iodide staining in sub-G1 phase (the solid line in sub-G1 phase). When ChangX-34 cells were treated with adriamycin, similar redistribution of cell cycle was also observed (Table 1) . The responsiveness to adriamycin in these cells was further con®rmed by trypan blue exclusion assay (Table 2) . Although the proliferation rates dier between two cell lines, adriamycin treatment not only signi®cantly slowed the proliferation rates of Chang and ChangX-34 cells but also increased cell death. Together, data demonstrated that cells with cytoplasmic sequestration of p53 protein still retained the sensitivity to chemotherapeutic drugs, which mainly caused p53-mediated cellular response.
The increased p53 promoter activity is accompanied by the increased free p53 protein A puzzle we have not solved yet is how adriamycin restores the function of p53 protein in ChangX-34 cells. Since cellular exposure to a variety of genotoxic stress increased cellular p53 level through rapid phosphorylation and acetylation of p53 protein (Chresta et al., 1996; Morgan and Kastan, 1997; Giaccia and Kastan, 1998) , we assumed that modi®cation sites of p53 protein in ChangX-34 cells were still available and we asked how eciently adriamycin would restore the function of p53 in ChangX-34 cells. When ChangX-34 Figure 5 Analysis of cell cycle distribution after adriamycin treatment. Chang or ChangX-34 cells were cultivated in the medium of DMEM containing 10% fetal bovine serum and treated with adriamycin with/without doxycycline for 36 h and stained with propidium iodide. Stained cells were analysed in a FACScan (Beckton Dickinson)¯ow cytometer. Red color indicates cells in G1 phase (large peak) or G2/M phase (small peak), the hatched area for cells in S phase and blue color for cell debris. The propidium iodide staining in sub-G1 phase (the solid line in the sub-G1 phase) is proportionally increased with the population of cell debris after adriamycin treatment Oncogene Reversible p53 activity in HBx-expressing liver cells C Yun et al cells were treated with sub-maximal doses of adriamycin (0.1 and 0.5 mg/ml) in the presence of doxycycline, a dose-dependent increase of p53-dependent CAT activity was observed. The p53-dependent CAT activity was increased by 2 ± 3-fold at the concentration of 0.1 mg/ml, by 6 ± 8-fold at 0.5 mg/ml and more than 15-fold at 1 mg/ml of adriamycin ( Figure 6a ) where a signi®cant amount of HBx was still present ( Figure  6b ). In fact, we found that high doses of adriamycin (1 mg/ml) actually enhanced the level of HBx protein, but there was a maximal increase in p53-mediated transcriptional activity. Therefore, we next examined whether adriamycin would aect the HBx/p53 interaction. Direct Western analysis again showed the high p53 protein level in adriamycin-treated cells (Figure 6c , upper panel). These cell lysates were immunoprecipitated with anti-HBx antibody and the immunoprecipitated p53 protein (Figure 6c , middle panel) as well as free p53 protein in the supernatant (Figure 6c , lower panel) were determined by Western blot analysis. We found that a considerable amount of p53 protein still remained bound to HBx protein. However, a signi®-cant dierence was also observed at the level of free p53 protein in adriamycin-treated cells. Thus, the data show that adriamycin in ChangX-34 cells eciently enhances the p53-mediated transcriptional activity, which is triggered by the increased free p53 protein.
Discussion
HBx protein is a multifunctional protein that can bind to several dierent cellular proteins. These included CREB and ATF2 (Macguire et al., 1991) , TATAbinding protein (Quadri et al., 1995) , RNA polymerase subunit RBP5 (Cheong et al., 1995) , p53 tumor suppressor protein (Truant et al., 1995; Lin et al., 1997) and XAP-1, a probable DNA repair protein (Becker et al., 1998) . Although the functional signi®cance of these protein-protein interactions in human liver cells was not clearly understood, these protein- protein interactions were considered as one of the main mechanisms in contributing to the development of liver cancer through modulation of gene expression. Among these proteins, p53 is an important common target site in the pathogenesis of DNA tumor virus. It is suggested that disruption of p53 activity is prerequisite for ecient viral replication as well as deranged cell cycle control in host cells (Lee et al., 1995; Doitsh and Shaul, 1999) . However, no one has clearly demonstrated in vivo association of HBx with p53 in human liver cells due to diculties in detecting endogenous p53 protein (Ullrich et al., 1993; Wieczorek et al., 1996) and HBx protein (Urban et al., 1997; Qin et al., 1998) . As far as we know, this is the ®rst report elucidating in vivo association between HBx and p53 proteins by both biochemical (Figure 2 ) and immunocytochemical methods (Figure 3) . Our data support the previous observation showing the cytoplasmic retention in HepG2 cells after co-transfection of HBx and p53 plasmids (Takada et al., 1997) . The functional interference of p53 protein by HBx protein is demonstrated by the reduction of the p53-mediated transcriptional activation (Figure 4a ) and partial inhibition of p21 WAF1 mRNA (Figure 4b ) in the presence of doxycycline. It is possible that partial inhibition of p21 WAF1 mRNA can result from the previous ®nding that HBx increases TGF-b expression, which is known to up-regulate the p21 WAF1 gene (Yoo et al., 1996) . Further, we showed that the basal level of HBx in ChangX-34 cells is able to change the location of p53 in some cells (Figure 3) , suggesting that HBxbinding to p53 in vivo is as ecient as in vitro (Elmore et al., 1997; Lin et al., 1997) .
Disruption of p53 activity by viral oncoproteins is frequently found during viral carcinogenesis and thought to be equivalent to mutation of p53 gene in cells. Mutation of p53 gene in cells causes not only deregulation of cell cycle control but also altered responses to anticancer therapies (Kim et al., 1998b; reviewed in Houghton, 1999) . Here, we demonstrated that p53 protein sequestered in the cytoplasm is translocated to the nucleus by treatment with adriamycin, anticancer drug (Figure 3b ). At the same time, nuclear translocation of p53 protein is accompanied by the restoration of p53 activity as demonstrated by the increased transcriptional activity at the p53-responsiveness DNA elements as well as increase of p21 WAF1 mRNA expression in ChangX-34 cells (Figure 4) . This is the ®rst report demonstrating that functional inactivation of p53 protein by HBx protein is reversible and our results may provide a new insight in anticancer therapies. It is known that loss of p53 function due to mutation in p53 gene frequently interferes with responses of cancer cells to anticancer therapies and thereby is used as a major predictor of failure in anticancer therapies (reviewed in Weller, 1998; Bunz et al., 1999) . Therefore, a signi®cant number of trials have been tried to deliver wild-type of p53 gene into cancer cells with nonfunctional p53 gene (Harris et al., 1996; McCormick, 1999) . Unlike mutation of p53 gene in cells, loss of p53 function induced by HBx protein can be restored. As shown in Tables 1 and 2 and Figure 5 , ChangX-34 cells are eectively arrested or undergo apoptosis (Tables 1 and 2 ) with concomitant recovery of p53 function upon adriamycin treatment (Figures 4  and 6) . Thus, our results clearly elucidate that functional inhibition of p53 protein induced by HBx protein can be restored by treatment with adriamycin. However, we have recognized that adriamycin treatment appears to be less potent in ChangX-34 cells than it does in Chang cells. Therefore, it seems that HBx partly negates the eect of adriamycin in ChangX-34 cells due to the partial lack of checkpoint function. Anyhow, these results suggest that cells with p53 protein modulated by viral oncoproteins such as SV40 T antigen, E6 or EIB55K may lose p53-mediated checkpoint function but still retain the sensitivity to anticancer therapies. p53-mediated cellular responses include activation of several genes involved in the execution of apoptosis or G1 arrest (McCurrach et al., 1997; MuÈ ller et al., 1997; Houghton, 1999; Wu et al., 1999) . Further study elucidating whether other anticancer drugs or irradiation triggers similar cellular responses will be taken for granted.
It is well known that the cellular p53 level is increased in response to dierent cellular stresses. This is mainly achieved by covalent modi®cation of p53 molecule and modulation of Mdm2 activity (Oren, 1999) . So far, no one has demonstrated that the p53 molecule interacting with viral oncoprotein, not free p53 protein, can be eciently increased by genotoxic cellular stresses. The C-terminal domain of HBx protein (aa 110 ± 154) was shown to be necessary for ecient binding to GST-p53 protein (Elmore et al., 1997) and later the binding domain was further narrowed down to a small region of HBx transactivation domain (aa 102 ± 136) (Lin et al., 1997) . Meanwhile, the interaction site of p53 was identi®ed in either the DNA-binding domain or the oligomerization domain, and a small fragment of p53 (aa 315 ± 393) was enough to bind to HBx protein eciently (Lin et al., 1997) . Therefore, it is possible that the C-terminal fragment of p53 protein binds HBx protein and remaining part of p53 protein is still available for modi®cations or interaction with other proteins after adriamycin treatment. The increased p53 level in ChangX-34 cells upon adriamycin (Figures 3 and 4) supports this hypothesis. It is recent understanding that p53 protein can be phosphorylated on a number of dierent sites, increasing its half-life and transactivation activity by irradiation (reviewed in Amundson et al., 1998) . Among several phosphorylation sites, phosphorylation at serine-15 is thought to be critical in the functional activation of p53 protein during cellular stress. Many dierent kinases including DNA-PK and ATM kinase are responsible for the phosphorylation of the p53 molecule (Tibbetts et al., 1999) . Currently, it is not known whether chemotherapeutic drugs such as adriamycin also trigger phosphorylation of serine-15, which resides at the Nterminal domain of p53 protein.
It can be assumed that modi®cation of p53 protein by adriamycin in ChangX-34 cells not only causes the stabilization of p53 protein but also may trigger the dissociation of p53 molecule from the HBx:p53 complex. Our data elucidated that p53-dependent transcriptional activation can be induced with low doses of adriamycin (0.1, 0.5 mg/ml) with which little increase in p53 protein was accompanied (Figure 6b ). These results suggest that rapid modi®cation of p53 molecule upon adriamycin treatment may trigger conformational change of p53 protein, resulting in dissociation of p53 from HBx. When ChangX-34 cells were treated with adriamycin, a considerable amount of p53 molecules still remained bound to HBx protein (Figure 6c ). At the same time, free p53 molecule was signi®cantly increased in adriamycin-treated ChangX-34 cells, supporting that some p53 molecules can be dissociated from the HBx:p53 complex. On the other hand, an intense staining of p53 protein upon adriamycin treatment was almost exclusively found in the nucleus but not in the cytoplasm of ChangX-34 cells (Figure 3) . In fact, we had expected that some of p53 molecules should be visible in the cytoplasm or at nuclear periphery even after adriamycin treatment. It is possible that anti-p53 antibody recognizes free nuclear p53 molecules better than the p53:HBx complex. It is also plausible that we may not clearly distinguish p53 protein if the HBx:p53 complex mainly locates at the nuclear periphery in adriamycin-treated ChangX-34 cells cells.
Given that modi®cation of p53 upon adriamycin triggers the accumulation of free p53 molecules, one possibility is that an increase in cellular p53 level accelerates oligomerization of p53 molecules. As mentioned in the above, the oligomerization domain of p53 protein is involved in interaction with HBx (Lin et al., 1997) . If oligomerization of p53 molecules were a rate-limiting step, it would be possible that an increase in cellular p53 level accelerated oligomerization of p53 molecules, thereby preventing its interaction with HBx protein. Another possibility is that adriamycin treatment rapidly and eciently induces modi®cation of p53 protein that triggers conformational change of p53 protein, resulting in dissociation of p53 from HBx protein. This hypothesis is also supported by previous observation (Price and Park, 1994; Selvakumaran et al., 1994 ) that increased DNA binding activity at the p53-binding sites was observed without any increase of p53 protein levels. Furthermore, disruption of p53/Tantigen complex was recently reported when T-antigen transformed cells were exposed to oxidative stress (Gonin et al., 1999) . Thus, activation process of p53 protein upon adriamycin treatment eciently occurs even when p53 protein remained bound to HBx protein. Together, our ®ndings demonstrate that HBx protein inhibits the function of p53 protein through its cytoplasmic retention and this functional inhibition can be restored upon treatment with adriamycin. The ®ndings reported in this work should contribute to provide a new insight in the rational regimens for anticancer therapies.
Materials and methods
Antibodies
Primary rabbit anti-HBx antibodies against the HBx synthetic peptides spanning 80 ± 94 and 144 ± 154 amino acid residues were prepared. Rabbit anti-hemagglutinin (HA) antibody (Santa Cruz) and rabbit anti-p53 (DAKO) as well as the mixture of mouse anti-p53 antibodies (Oncogene Science) were purchased.
Establishment of HBx-expressing Chang cell lines
Human Chang liver cells were maintained in DMEM containing 10% FBS (fetal bovine serum). The plasmids of pTetX and pUHD172-1 (Kim et al., 1998a) were cotransfected into Chang liver cells using lipofectamine (Gibco-BRL). The cells were split 2 days later and maintained in the presence of 400 mg/ml of G418 for 3 weeks. G418-resistant clones were selected and analysed for the induction of HBx protein after treatment with doxycycline.
Western blot analysis
Cells were extracted using RIPA (150 mM NaCl, 10 mM Tris, pH 8.0, 0.5% Triton X-100, 0.1% SDS, 0.5% deoxycholate, 0.1 mM PMSF, 0.1% aprotinin) buer at 48C. The extracts were centrifuged in a microcentrifuge for 5 min and the supernatants as well as the pellets were subjected to SDS ± PAGE and transferred to the nitrocellulose membrane. The membranes were blocked in 5% (w/v) non-fat dried milk in TBS (20 mM Tris, 137 mM NaCl, pH 7.6) and then incubated with appropriate primary antibodies. Secondary antibodies conjugated with horseradish peroxidase were used and immunoreactive proteins were detected using the ECL system (Amersham).
Immunoprecipitation
ChangX-34 cells were collected and lysed using RIPA buer. The total cell lysates were reacted with either a mixture of anti-p53 antibodies or mouse IgG in GBT buer (10% glycerol, 50 mM HEPES, pH 7.5, 170 mM KCl, 7.5 mM MgCl 2 , 0.1 mM EDTA, 0.1 mM DTT, 1% Triton X-100). After incubating the above reaction mixtures at 48C for 1 h, preswollen protein A-Sepharose beads (Pharmacia LKB) were added. The samples were further incubated for 1 h at 48C, washed three times with washing buer (10 mM Tris, pH 7.5, 0.1% NP-40) and boiled with sample buer. The eluted proteins were subjected to Western blot analysis using anti-HA antibody.
Immunofluorescence staining
Cells were cultivated on a cover slip and treated with doxycycline (2 mg/ml), if necessary. Cells were directly ®xed in a cold mixture of methanol/acetone for 10 min and permeabilized. Cells were incubated with either anti-HA antibody or the mixture of anti-p53 antibodies and subsequently incubated with Cy3-conjugated goat anti-mouse IgG or FITC-conjugated goat anti-rabbit IgG (Jackson ImmunoResearch Laboratories). Expression and localization of the proteins were observed under a¯uorescence microscope.
Northern blot analysis
Total RNA was isolated from Chang or ChangX-34 cells using guanidinium thiocyanate-phenol-chloroform method. Twenty mg of total RNA was separated on a formaldehydedenaturing gel and transferred to a nitrocellulose membrane. Transferred RNA was hybridized with 32 P-labeled cDNA and the membrane was exposed to X-ray ®lm.
CAT assay
G5BCAT or p53CAT reporter plasmid (Jiang et al., 1993) was transfected into Chang or ChangX-34 cells using DOTAP liposomal transfection reagents (Boehring Mannheim) according to manufacturer's protocol. Six hours later, cells were treated with adriamycin and doxycycline, if needed, for 36 h. Cells were harvested and extracted through three cycles of freeze/thaw. CAT enzyme assay was performed on the basis of an equal amount of protein lysates according to the assay protocol provided by Promega. We did not use any other internal reference plasmids that are constructed under the control of viral promoter/enhancer. We consistently found that HBx enhanced many viral promoters/enhancers. Brie¯y, an aliquot of cell extracts was incubated with [ 3 H]chloramphenicol (30 ± 60 Ci/mmol, DuPont NEN) and butyryl-CoA for 3 h and the reaction was terminated by adding TMPD/xylene mixture. The radioactivity of butyrylated chloramphenicol was measured by Liquid Scintillation Counter (Wallac Pharmacia).
FACS analysis
Chang and ChangX-34 cells were treated with adriamycin and doxycycline for 36 h, lysed with Nonidet P-40 and stained with propidium iodide using CycleTEST TM plus DNA reagent kit (Becton Dickinson) according to the manufacturers. Stained cells were analysed in a FACScan (Becton Dickinson)¯ow cytometer using ModFit LT cell cycle software program.
Trypan blue exclusion assay
Chang and ChangX-34 cells cells were seeded in a 24-well plate at a density of 5610 4 cells. Next day, cells were treated with 1 mg/ml of adriamycin in the presence/absence of doxycycline for 36 h. Viable and dead cells were counted after trypan blue staining using haemocytometer.
